KCM
SNDX icon

Kynam Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Kynam Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-400,000
Closed -$5.81M – 32
2023
Q3 		$5.81M Buy
+400,000
New +$7.57M 0.95% 19

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Kynam Capital Management's SNDX Position: Q2 2026 in Review

Kynam Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 8,050,959 shares worth $176M. The position accounts for 9.73% of the portfolio, ranked #2.

Kynam Capital Management first reported a position in SNDX in Q4 2021 and has held it in 19 quarters since. The position peaked at $188M in Q1 2026. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Kynam Capital Management held 8,050,959 shares of Syndax Pharmaceuticals worth $176M as of Q2 2026.
  • Kynam Capital Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up 9.73% of Kynam Capital Management's portfolio in Q2 2026, its #2 holding.
  • Kynam Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Kynam Capital Management's Syndax Pharmaceuticals position peaked at $188M in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.